Abstract Instructions

Abstracts should only be submitted online through the Abstract Submission Form available after sign up on MyDeltaCure

Abstract Submission Deadline (only for Poster Exhibition): July 29th, 2024 (Monday)

Abstract acceptance notification: August 26th, 2024 (Monday)

Abstracts should be submitted in English. Abstract body text is limited to 3.000 characters including spaces. It is possible to attach a file (3 MB max) with graphs/images (not in the abstract text body).

It is possible to re-submit abstracts which have already been presented at one previous national or international meeting. However, work that has already been published as a full original paper cannot be accepted.

Choose from the established list of topic categories:

Virology and Pathogenesis

• Virology: the latest insights
• Pathogenesis: insights from liver biopsies
• Are immune responses important in HDV infection?
• New HBV biomarkers: any role in HDV?

Diagnosis, Staging, HCC risk and antiviral therapy

• HDV-RNA assays: performances and clinical challenges
• Fibroscan and other non-invasive markers
• PegIFN+NUC: predictors of response

Current and new antiviral treatments

• Bulevirtide mono and combo in clinical trials
• Bulevirtide in EU: SAVE-D study update
• Bulevirtide in France: multicenter study update
• Bulevirtide for decompensated cirrhosis
• Bulevirtide in HIV coinfected patients
• Can we stop Bulevirtide? Lessons learned from viral kinetics modelling
• What have we learned from the Lonafarnib and pegIFN lambda trials?
• New antivirals for HDV, phase II studies
• What can we learn from HBV trials for HDV cure?

After abstract submission, a confirmation message will be sent by e-mail. In case you do not receive the message in a few minutes, please contact the Organizing Secretariat via email at this address: deltacure2024@effetti.it

The author who submits the abstract will be considered the Presenting Author and is responsible for delivering poster presentation if the abstract is accepted:

• He/she is responsible for the accuracy of the abstract in all its parts ensuring that the first author and all co-authors have agreed with the content of the abstract.
• He/she will receive via email the official communications from the Organizing Secretariat.
• Abstract will be accepted only for poster exhibition. Poster orientation will be portrait (vertical), size 70 x h 100 cm
• The Organizing Secretariat will take care of the printing of the posters that will be made available at the congress venue
• Posters will be fixed by the Presenting Author in the Poster Exhibition Area of the Meeting Venue
• All accepted posters will be published in the Delta Cure Meeting Repository